LiDCO Group has received approval in China for its LiDCOrapidhaemodynamic monitor.
This means that it can be relaunched later this year. The approval was required because of the need to register a key component of the monitor and this held back sales in the past two years. China is the second largest market in the world.
Annual sales could exceed £500,000. There is little in the current forecasts for revenues from China. The group loss is expected to decline from £2m to £1.1m this year.
© 2020 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.